Identifying life science breakthroughs to address unmet clinical needs, we invest in translational medicine frontiers to capture China opportunities.
Positioning
Alwin Capital is a professional venture capital in China specializing in life science investments. Driven by theme-focused research in life science, Alwin Capital has developed investment strategies that capture outstanding opportunities for innovative diagnostic and therapeutic developments. We are committed to the long-term investment in life science with the pursuit of the excess investment return based on the scientific insights.
Founded in 2015, Alwin Capital was formed by former CICC senior executives, bringing in decades of experience in healthcare research and medical markets. Alwin Capital currently manage four venture funds with more than RMB 2 Billion in AUM, having invested in dozens of companies in life science and cultivated a bunch of leading companies in respective segments.
Portfolio
Over the past two decades, life science discoveries have been transformed into clinical applications and solutions, revealing a whole new horizon for healthcare industries. In the theme line based on gene sequencing, the industrial chain of molecular diagnosis has developed in an all-round way. In the theme line based on gene synthesis, drug research and development has entered the macromolecular platform from the small molecular platform, and then entered the living drug platform. In the theme line based on gene editing, new clinical technologies such as gene therapy have infiltrated the real clinical scenario. At the same time, life science, driven by artificial intelligence technology, has stepped a new development stage of digital life and precision medicine.
Under the current background of the development of life science and clinical medicine, adhering to the professional investment research in life science and the profound understanding of portfolio management, Alwin Capital has formed a systematic investment layout covering Innovative Drugs, Molecular Diagnostics, Innovative Hardware, Scientific Services and AI Applications.
The leader in gene editing new drug R&D in China with its product for β-thalassemia obtaining the first IND of gene therapy drugs in China
Reforgene
The company with cutting-edge CRISPR technology in both in-vitro and in-vivo gene therapy product pipelines
NuiGene
Innovative gene therapy company based on both AAV platform and CRISPR technology
immorna
mRNA drug discovery company with systematic layout in vaccines of infectious diseases and I/O drugs
Neocura
mRNA R&D company in China with pipelines of tumor neoantigen vaccines and other I/O drugs
Cell Therapy-Uni-CAR
CAR-T cell therapy company with its first-in-class candidate of IL-6 knockdown CD19 CAR-T targeting CNS leukemia
Xbiome
Microbiome drug R&D company in China with global leading progress and advancement
Bliss Bio
ADC drug R&D company with a seasoned management team
Kira Pharma
Complement drug R&D company founded by globally prestigious scientist in the field of complement system
Adlai Nortye
O/I drug R&D company with a strong immunotherapy tumor pipeline entering phase III clinical trials.
Cancer Liquid Biopsy-Genecast
The leading company in the field of tumor liquid biopsy in China, providing a full solution for tumor companion diagnosis
Mass Spectrometry Testing-Yingsheng Biology
The key player in mass spectrometry testing market with a pipeline covering core products in China
Genetic Disease Testing-Chigene
Genetic disease testing company with the largest database of genetic disease patients in China
Molecular Pathology Platform-Geneis:
Multi-platform molecular pathology service provider to hospitals with comprehensive capabilities
Forensic DNA Testing-SuperBio
The leader in forensic DNA testing with patented technologies and devices in China
DTC Gene Testing-23 MoFang
The largest DTC gene testing company in China accounting for 40% market share
Synbio Tech
High-throughput gene synthesis company with exploration of in de novo design and synthesis of antibodies
Frasergen
Scientific research service provider with advanced 3rd generation gene sequencing techniques
ONT Nanopore Sequencing-Qitan Tech
ONT nanopore sequencer R&D company with the most advanced progress in China
Micro Droplet Platform-Sniper
Digital PCR R&D company with innovative droplet generation technology platform
Edge Medical
The leading surgical robot company in China with both single-hole and multi-hole endoscopic surgical robots in the pipeline
Rossum Robot
A star-up company in the field of orthopedic robotics with its pelvic fracture reduction surgical robot holding global advancement
R&D
The R&D company of high-value consumables for neural intervention with a complete product pipeline
FFR-CT AI Software-Keya Medical
The leading AI image diagnosis company whose FFR-CT approved as the first AI Class III medical device by CFDA
Radiotherapy AI Software-Datu Medical
AI imaging software company of radiotherapy with its planning software was first approved as the Class III medical device by CFDA
Click
Digital manufacturer of invisible appliance based on automatic 3D printing technology
Edigene
The leader in gene editing new drug R&D in China with its product for β-thalassemia obtaining the first IND of gene therapy drugs in China
Reforgene
The company with cutting-edge CRISPR technology in both in-vitro and in-vivo gene therapy product pipelines
NuiGene
Innovative gene therapy company based on both AAV platform and CRISPR technology
immorna
mRNA drug discovery company with systematic layout in vaccines of infectious diseases and I/O drugs
Neocura
mRNA R&D company in China with pipelines of tumor neoantigen vaccines and other I/O drugs
Cell Therapy-Uni-CAR
CAR-T cell therapy company with its first-in-class candidate of IL-6 knockdown CD19 CAR-T targeting CNS leukemia
Xbiome
Microbiome drug R&D company in China with global leading progress and advancement
Bliss Bio
ADC drug R&D company with a seasoned management team
Kira Pharma
Complement drug R&D company founded by globally prestigious scientist in the field of complement system
Adlai Nortye
O/I drug R&D company with a strong immunotherapy tumor pipeline entering phase III clinical trials.
Cancer Liquid Biopsy-Genecast
The leading company in the field of tumor liquid biopsy in China, providing a full solution for tumor companion diagnosis
Mass Spectrometry Testing-Yingsheng Biology
The key player in mass spectrometry testing market with a pipeline covering core products in China
Genetic Disease Testing-Chigene
Genetic disease testing company with the largest database of genetic disease patients in China
Molecular Pathology Platform-Geneis:
Multi-platform molecular pathology service provider to hospitals with comprehensive capabilities
Forensic DNA Testing-SuperBio
The leader in forensic DNA testing with patented technologies and devices in China
DTC Gene Testing-23 MoFang
The largest DTC gene testing company in China accounting for 40% market share
Synbio Tech
High-throughput gene synthesis company with exploration of in de novo design and synthesis of antibodies
Frasergen
Scientific research service provider with advanced 3rd generation gene sequencing techniques
ONT Nanopore Sequencing-Qitan Tech
ONT nanopore sequencer R&D company with the most advanced progress in China
Micro Droplet Platform-Sniper
Digital PCR R&D company with innovative droplet generation technology platform
Edge Medical
The leading surgical robot company in China with both single-hole and multi-hole endoscopic surgical robots in the pipeline
Rossum Robot
A star-up company in the field of orthopedic robotics with its pelvic fracture reduction surgical robot holding global advancement
R&D
The R&D company of high-value consumables for neural intervention with a complete product pipeline
FFR-CT AI Software-Keya Medical
The leading AI image diagnosis company whose FFR-CT approved as the first AI Class III medical device by CFDA
Radiotherapy AI Software-Datu Medical
AI imaging software company of radiotherapy with its planning software was first approved as the Class III medical device by CFDA
Click
Digital manufacturer of invisible appliance based on automatic 3D printing technology
Team
Alwin’s founding partners have been working together for nearly ten years, building a strong team culture and mutual trust over the course of their investment careers. They believe in science and the power of research. They all work in the front line to follow their beliefs and principles across their investment process. Strongly supported by a high-profile advisory board from the industry and capital market as well, Alwin is on track to explore and capture the investment opportunities in life science.
